Christophe Loretan
Keine laufenden Positionen mehr
Vermögen: 51 336 $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Christophe Loretan
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Novozymes Switzerland AG
2
| Subsidiary | 2 | |
Tillotts Pharma AG
Tillotts Pharma AG Pharmaceuticals: MajorHealth Technology Tillotts Pharma AG manufactures pharmaceuticals for treatment of gastrointestinal diseases. The firm specializes in the therapy of the lower gastrointestinal tract. It offers Asacol, Entocort, Colpermin, Tillhepo and VistaPrep. The company was founded in 1986 and is headquartered in Ziefen, Switzerland.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Christophe Loretan
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
CP Kelco ApS
CP Kelco ApS Food: Major DiversifiedConsumer Non-Durables CP Kelco ApS manufactures xanthan gum, pectin, and carrageenan. It also manufactures hydrocolloid solution products such as thickeners, gelling agents, and stabilizers. The company offers services to the food, pharmaceutical, oral care, personal care, household, and oilfield drilling industries. It also operates in North America, Europe, Asia and Latin America. CP Kelco was founded in 1934 and is located in Lille Skensved, Denmark. | Food: Major Diversified | Director/Board Member | |
The University of Texas at Austin | College/University | Doctorate Degree | |
The University of Colorado | College/University | Undergraduate Degree | |
Copenhagen Business School | College/University | Undergraduate Degree | |
Technical University of Denmark | College/University | Doctorate Degree | |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Director/Board Member | |
Novozymes BioloAg A/S
Novozymes BioloAg A/S BiotechnologyHealth Technology Novozymes BioloAg A/S provides research and development for biotechnology products and processes. It participates in The BioAg Alliance to commercialize BioAg assets and competencies within microbial research, development, and production. The company was founded on October 22, 2007 and is headquartered in Bagsvaerd, Denmark. | Biotechnology | Chief Executive Officer | |
CAMLIN FINE SCIENCES LIMITED | Chemicals: Specialty | Director/Board Member | |
EVOLVA HOLDING SA | Food: Specialty/Candy | Director/Board Member | |
Novozymes Biopharma DK A/S
Novozymes Biopharma DK A/S Pharmaceuticals: MajorHealth Technology Novozymes Biopharma DK A/S engages in the wholesale of pharmaceuticals and medical article. The firm operates and invests in research, development, production, and trade in biological solutions, including pharmaceuticals, and biotechnology products and processes.The company was founded on May 29, 2006 and is headquartered in Bagsvaerd, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Novozymes Bioindustrial China A/S
Novozymes Bioindustrial China A/S BiotechnologyHealth Technology Novozymes Bioindustrial China A/S invests in research and development as well as production of biotechnological products and processes. The company was founded on January 1, 1999 and is headquartered in Bagsvaerd, Denmark. | Biotechnology | Director/Board Member | |
Albumedix A/S
Albumedix A/S Pharmaceuticals: MajorHealth Technology Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Evolva AG | Director/Board Member | ||
Protera SAS
Protera SAS Food: Major DiversifiedConsumer Non-Durables Protera SAS manufactures protein-based ingredients to address critical challenges in food, agriculture, the environment, and human health. Its products include Guard, Sense, antioxidant proteins, and foaming and emulsifying proteins. The company was founded by Leonardo Álvarez and Francia Navarrete and is headquartered in Neuilly-sur-Seine, France. | Food: Major Diversified | Chairman | |
Enduro Genetics ApS
Enduro Genetics ApS Miscellaneous Commercial ServicesCommercial Services Enduro Genetics ApS is a Danish biotechnology research company that specializes in developing bio products. The company is based in Copenhagen, Denmark. Enduro Genetics was founded by Peter Rugbjerg and Christian Munck. The CEO is Christian Munch. | Miscellaneous Commercial Services | Director/Board Member |
Statistik
International
Dänemark | 11 |
Schweiz | 4 |
Vereinigte Staaten | 3 |
Kanada | 2 |
Indien | 2 |
Sektoral
Health Technology | 7 |
Consumer Services | 5 |
Process Industries | 4 |
Consumer Non-Durables | 4 |
Commercial Services | 3 |
Operativ
Director/Board Member | 11 |
Corporate Officer/Principal | 5 |
Chief Operating Officer | 2 |
Doctorate Degree | 2 |
Undergraduate Degree | 2 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Thomas Videbaek | 16 |
Andrew Fordyce | 6 |
Hansueli Schaub | 1 |
- Börse
- Insiders
- Christophe Loretan
- Unternehmensverbindungen